Back to Search
Start Over
Risk factors of recurrent secondary hyperparathyroidism after adequate primary surgical treatment.
- Source :
-
Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2023 Feb 03; Vol. 14, pp. 1063837. Date of Electronic Publication: 2023 Feb 03 (Print Publication: 2023). - Publication Year :
- 2023
-
Abstract
- Background: Secondary hyperparathyroidism (SHPT) is a common condition in patients with end-stage renal disease (ESRD) who are on dialysis. Parathyroidectomy is a treatment for patients when medical therapy has failed. Recurrence may occur and is indicated for further surgery in the era of improved quality of care for ESRD patients.<br />Methods: We identified, 1060 patients undergoing parathyroidectomy from January, 2011 to June, 2020. After excluding patients without regular check-up at our institute, primary hyperparathyroidism, or malignancy, 504 patients were enrolled. Sixty-two patients (12.3%, 62/504) were then excluded due to persistent SHPT even after the first parathyroidectomy. We aimed to identify risk factors for recurrent SHPT after the first surgery.<br />Results: During the study period, 20% of patients who underwent parathyroidectomy at our institute (in, 2019) was due to recurrence after a previous parathyroidectomy. There were 442 patients eligible for analysis of recurrence after excluding patients with the persistent disease (n = 62). While 44 patients (9.95%) had recurrence, 398 patients did not. Significant risk factors for recurrent SHPT within 5 years after the first parathyroidectomy, including dialysis start time to first operation time < 3 years ( p = 0.046), postoperative PTH >106.5 pg/mL ( p < 0.001), and postoperative phosphorus> 5.9 mg/dL ( p = 0.016), were identified by multivariate analysis.<br />Conclusions: The starting time of dialysis to first operation time < 3 years in the patients with dialysis, postoperative PTH> 106.5 pg/mL, and postoperative phosphorus> 5.9 mg/dL tended to have a higher risk for recurrent SHPT within 5 years after primary treatment.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2023 Kuo, Wang, Hung, Hsu, Kou, Chen, Tsai, Chang, Wang, Hsu, Yeh, Lee and Yeh.)
Details
- Language :
- English
- ISSN :
- 1664-2392
- Volume :
- 14
- Database :
- MEDLINE
- Journal :
- Frontiers in endocrinology
- Publication Type :
- Academic Journal
- Accession number :
- 36817581
- Full Text :
- https://doi.org/10.3389/fendo.2023.1063837